Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zilovertamab - Oncternal Therapeutics

Next Previous
Drug Profile

Zilovertamab - Oncternal Therapeutics

Alternative Names: Cirmtuzumab - Oncternal Therapeutics; UC-961

Latest Information Update: 15 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer California Institute for Regenerative Medicine; Oncternal Therapeutics, Inc.; UC San Diego School of Medicine; University of California, San Diego
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Receptor tyrosine kinase-like orphan receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Phase I/II Mantle-cell lymphoma
  • Phase I Prostate cancer
  • Preclinical Endometrial cancer; Ovarian cancer
  • No development reported HER2 negative breast cancer

Most Recent Events

  • 26 Feb 2024 Oncternal Therapeutics in collaboration with MD, University of California completes a phase I trial in Her2 negative Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT02776917)
  • 07 Feb 2024 Updated efficacy data from a phase I/II trial in Chronic lymphocytic leukaemia released by Oncternal Therapeutics
  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Mantle cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top